Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Medically Tailored Meals to Reduce Ultra-processed Food Intake in Colorectal Cancer Survivors (MTM)

8 juillet 2026 mis à jour par: Mengxi Du, Massachusetts General Hospital

A Pilot Medically Tailored Meal-Based Intervention to Reduce Ultra-processed Food Intake Among Patients With Stages I-III Colorectal Cancer

This research study is a three-arm, parallel-group randomized clinical trial that examines the feasibility and initial impact of consuming medically tailored meals to reduce intake of ultra-processed food and improve health and survival outcomes among 60 patients with stage I-III colorectal cancer.

Aperçu de l'étude

Description détaillée

This research study is exploring whether medically tailored meals can help survivors with stage I-III colorectal cancer reduce their intake of ultra-processed foods and improve their health. Ultra-processed foods, such as packaged snacks, fast food, and sugary drinks, make up a large portion of many Americans' diets and have been linked to a higher risk of colorectal cancer and poorer survival. While experts recommend limiting these foods, many patients face challenges like limited time, cooking skills, or access to healthy options, making dietary changes difficult.

Medically tailored meals, designed by dietitians to meet specific health needs, may offer a practical solution by making healthy eating easier and more accessible. This study will evaluate whether these meals, with or without fresh produce, can improve diet quality, support healthier gut bacteria, and reduce inflammation. Researchers will measure changes in gut health and blood markers before and after the program to better understand how diet can influence recovery and long-term outcomes for colorectal cancer survivors.

This research study will last about 3 years. It includes a 2-week preparation period, a 6-week intervention with a medically tailored meals (MTM) program, 2 clinic visits (one prior to starting and one following the 6-week intervention period), 2 nutrition counseling visits with a registered dietitian (also conducted before and after the intervention), and follow-up contacts (4 weeks after the final visit and then every year for 3 years).

Because it is unknown which meal plan is best, participants will be randomized to one of these 3 meal plan groups:

  • MTM: participants will receive 3 fully prepared, home-delivered, medically tailored meals per day for 6 weeks.
  • MTM plus Fresh Produce: participants will receive 2 fully prepared, home-delivered, medically tailored meals per day, plus weekly deliveries of fresh produce and accompanying recipes, for 6 weeks.
  • Control group: participants will receive weekly recipes and meal-planning materials only; no food will be provided.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02114
        • Massachusetts General Hospital
        • Contact:
        • Chercheur principal:
          • Mengxi Du, RD, PhD, MPH

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Participants must have histologically confirmed stage I, II, or III colon or rectal adenocarcinoma and have completed standard treatment (including surgery, chemotherapy, and radiotherapy) at least 2 months ago.
  • Age ≥18 years.
  • ECOG = 0 or 1
  • Participants must have a high intake of UPFs, defined as meeting at least three of the following criteria, each consumed on more than or equal to 3 days per week:

    • Ready-to-eat or ready-to-heat dishes, such as packaged frozen meals, prepared entrées, quick dishes, or microwaveable packaged foods;
    • Sugar- or artificially sweetened beverages (e.g., soda, diet coke, sweetened teas, bubble tea, flavored instant coffee mixes), alcoholic beverages, or other commercially prepared sweetened drinks;
    • Packaged snack foods, such as chips, cookies, ice cream, desserts, or other commercially prepared snack items;
    • Frequent fast-food consumption, including meals or beverages purchased from fast-food or quick-service restaurants, such as McDonald's, Wendy's, KFC, Burger King, Five Guys, Chick-fil-A, Dairy Queen, etc.
    • Home-cooked meals that rely primarily on pre-prepared ingredients, such as deli meats, canned fish, canned fruits and vegetables, frozen foods or ingredients, or similar products used more often than fresh produce, raw meat/seafood, or raw fruits and vegetables.
  • Subjects must be able and willing to follow study procedures and instructions.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants who are receiving any other investigational agents or lifestyle/dietary interventions.
  • Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol.
  • Any prior diagnosis of invasive (i.e., excluding intramucosal cancer) gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (except non-melanoma skin) in which there has been any active treatment within the last three years.
  • Presence of synchronous (at the same time) malignancy for which the patient is currently receiving active treatment.
  • Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.
  • Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, may increase the risks associated with study participation or study treatment, limit compliance with study requirements, or interfere with the interpretation of study results.
  • Participants who are pregnant Participants who may become pregnant or partners of those who may become pregnant while on study will receive contraception counseling. Participants or partners of those who become pregnant while participating in the study should immediately inform their doctor.
  • Participants who are unwilling to make dietary changes.
  • Individuals who do not have access to or are not able to participate in remote nutrition counseling and assessment sessions via Zoom or phone calls.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Medically Tailored Meals (MTM)
3 prepared meals per day (i.e., breakfast, lunch, and dinner) for a total of 126 meals.
3 fully prepared, home-delivered, medically tailored meals per day delivered weekly for 6 weeks.
Expérimental: Medically Tailored Melas (MTM) plus Fresh Produce
2 prepared meals per day (84 meals total), plus weekly fresh produce and recipes to help prepare a third meal each day.
2 fully prepared, home-delivered, medically tailored meals per day, plus weekly deliveries of fresh produce and accompanying recipes, for 6 weeks.
Comparateur actif: Control group
weekly meal planning materials and recipes only; no food will be provided.
weekly recipes and meal-planning materials only; no food will be provided.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Evaluation of feasibility of consuming medically tailored meals through study participation
Délai: From enrollment to the end of study, assessed at year 3 follow-up

Feasibility will be assessed by the following metrics:

• percentage of eligible patients who enroll

From enrollment to the end of study, assessed at year 3 follow-up
Evaluation of feasibility of consuming medically tailored meals through retention
Délai: From enrollment to the end of study, assessed at year 3 follow-up

Feasibility will be assessed by the following metrics:

• percentage of enrolled participants who complete study visits and outcome assessments

From enrollment to the end of study, assessed at year 3 follow-up
Evaluation of feasibility of consuming medically tailored meals through compliance
Délai: From enrollment to the final visit at 8 weeks

Feasibility will be assessed by the following metrics:

• proportion of participants who adhere to assigned interventions, defined as consumption of provided meals and/or produce (for intervention arms), completion of at least two dietary assessments, and provision of blood, tumor tissue, and fecal samples at baseline and end of intervention

From enrollment to the final visit at 8 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
MTM Impact on Diet
Délai: From enrollment to the end of study, assessed at year 3 follow-up
The extent to which the MTM-based intervention improves dietary intake and food insecurity across study arms
From enrollment to the end of study, assessed at year 3 follow-up
MTM Impact on Patient Outcomes
Délai: From enrollment to the end of study, assessed at year 3 follow-up
The extent to which the MTM-based intervention improves quality of life and patient-reported outcomes across study arms
From enrollment to the end of study, assessed at year 3 follow-up
Relative Composition of Gut Microbiome Features
Délai: From enrollment to the final visit at 8 weeks
Comparing change in gut microbiome features (species - to strain level specificity; metabolic pathways; enzymes) using deep meta'omic profiling in pre- and post- treatment samples.
From enrollment to the final visit at 8 weeks
Relative Composition of Gut Metabolites
Délai: From enrollment to the final visit at 8 weeks
Comparing change in gut metabolites using deep meta'omic profiling in pre- and post- treatment samples.
From enrollment to the final visit at 8 weeks
Change in Stool Metabolomics
Délai: From enrollment to the final visit at 8 weeks
Comparing change in stool metabolomics, using non-targeted global metabolomics analysis on stool samples to examine intensity changes in the stool metabolite profile.
From enrollment to the final visit at 8 weeks
Change in Plasma Metabolomics
Délai: From enrollment to the final visit at 8 weeks
Comparing change in plasma metabolomics, using non-targeted global metabolomics analysis on blood samples to examine intensity changes in the blood metabolite profile.
From enrollment to the final visit at 8 weeks
Longitudinal Biomarker Changes
Délai: From enrollment to the end of study, assessed at year 3 follow-up
Changes in clinical biomarkers using EHR data.
From enrollment to the end of study, assessed at year 3 follow-up
Longitudinal Disease Progression Changes
Délai: From enrollment to the end of study, assessed at year 3 follow-up
Changes in disease progression outcomes using EHR data.
From enrollment to the end of study, assessed at year 3 follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Mengxi Du, RD, PhD, MPH, Massachusetts General Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

10 août 2026

Achèvement primaire (Estimé)

10 août 2028

Achèvement de l'étude (Estimé)

10 octobre 2028

Dates d'inscription aux études

Première soumission

22 juin 2026

Première soumission répondant aux critères de contrôle qualité

8 juillet 2026

Première publication (Réel)

14 juillet 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

14 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

8 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Mengxi Du, RD, PhD, MPH. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Délai de partage IPD

Data can be shared no earlier than 1 year following the date of publication

Critères d'accès au partage IPD

Contact the MGB Innovation at PHSINNOVATIONSUPPORT@partners.org

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner